Rationales in the development of dissolution testing for solid oral dosage forms - An industrial, biopharmaceutical and regulatory perspective

Clinical Research and Regulatory Affairs

Volumn 15, Issue 3-4, 1998, Pages 187-207

  Fruitwala, M A ^a   Dondeti, P ^a   Alkhawam, E ^a   Ahmed, S ^a  

^a Barr Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; SALICYLIC ACID;

ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; DRUG APPROVAL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; ORAL DRUG ADMINISTRATION; QUALITY CONTROL;

EID: 0031772196     PISSN: 10601333     EISSN: None     Source Type: Journal    
DOI: 10.3109/10601339809109195     Document Type: Article

References (27)

1. Skoug, J.W , Halstead, G.W., Theis, D.L., Freeman, J.E., Fagan, D.T. and Rohrs, B.R. Strategy for the development and validation of dissolution tests for solid oral dosage forms. Pharm. Technol., 5, 58-72 (1996).
2. Dressman, J.B., Amidon, G.L., Reppas, C. and Shah, V.P. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm. Res., 15, 11-22 (1996).
3. The United States Pharmacopeia XXIII, United States Pharmacopeial Convention, Chapter 〈711〈, Rockville, MD, 1995.
4. Aiache, J.M., Aoyagi, N., Blume, H., Friedel, H.D., Grady, I.T., Hubert, B., Lesko, L., Qureshi, S. and Wirbitzki, E. FIP guidelines for dissolution testing of solid oral products. Dissol. Technol., 4, (4) 5-14 (1997).
5. Hollenbeck, R.G. and Takiar, N.B. In vitro evaluation of drug release from modified release delivery systems: Initial experience with calibrators for USP dissolution apparatus 3. Dissol. Technol., 4 (3) 5-8 (1997).
6. Das, S.K. and Gupta, B.K. Simulation of physiological pH-time profile in in vitro dissolution study. Relationship between dissolution rate and bioavailability of controlled release dosage form. Drug Dev. Ind. Pharm., 14, 537-544 (1988).
7. Blume H., Ali, S.L. and Siewert M Zur pharmazeutischen qualitat von glibenclamidehaltigen fertigarzneimitteln. Pharm. Ztg. 129, 983-989 (1984).
8. The United States Pharmacopeia XXIII, The United States Pharmacopeial Convention, Chapter 〈1088〉, Rockville, MD, 1995.
9. Davenport, H.W. Physiology of the gastrointestinal tract. Year Book Medical Publishers, 5th. Edition, Chicago, 1982.
10. Gray, V.A. USP dissolution standards - revisions, initiatives and new policies since 1980. The United States Pharmacopeial Convention, Pharm. Forum, 23 (3), 4183-4197 (1997).
11. In-process revision, The United States Pharmacopeial Convention, Pharm. Forum., 23 (1), 3423-3425 (1997).
12. Dressman, J.B., Berardi, R.R., Dermentzoglou, L.C., Russell, T.L., Schmaltz, S.P., Barnett, J.L. and Jarvenpaa, K. Upper gastrointestinal pH in young, healthy men and women. Pharm. Res., 7, 756-761 (1990).
13. Cummings, J.H., Pomare, E.W., Branch, W.J., Naylor, C.P. and MacFarlane, G.T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut, 28, 1221-1227 (1987).
14. Bronsted, H and Kopecek. Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm. Res., 9, 1540-1545 (1992).
15. Shah, V.P., Konecny, J.J., Everett, R.L., McCullough, B., Noorizadeh, A.C. and Skelly, J.P. In vitro dissolution profile of water-insoluble dosage forms in the presence of surfactants. Pharm. Res., 6, 612-618 (1989).
16. Finholt, P. and Solvang, S. Dissolution kinetics of drugs in human gastric juice: The role of surface tension. J. Pharm. Sci., 57, 1322-1326 (1968).
17. Qureshi, S.A. and McGilveray, I.J. Impact of different deaeration methods on the USP dissolution apparatus suitability test. Pharm. Forum., 20 (6), 8565 (1994).
18. Leeson, L.J. ANDA dissolution method development and validation. Dissol. Technol., 4 (1), 5-9 (1997).
19. Griffith, M.F., Curley, T.E. and Martin, G.P. Considerations in choosing a deaeration technique for dissolution media. Dissol. Technol., 4 (1), 16-17 (1997).
20. Shah, V.P., Lesko, L., Fan, Fleischer, N., Handerson, J., Makary, M., Ouderkirk, L., Roy, S., Sathe, P., Singh, G.J. and J. Song, Y and Williams, R. FDA guidance for industry: Dissolution testing of immediate release solid oral dosage forms. Dissol. Technol., 4 (4), 15-22 (1997).
21. Malagelada, J.R., Robertson, J.S., Brown, M.L, Remington, M., Duenes, J.A., Thomforde, G.M. and Carryer, P.W. Intestinal transit of solid and liquid components of a meal in health. Gastroenterology, 87, 1255 (1984).
22. Amidon, G.L., Lennernas, H., Shah, V.P. and Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420 (1995).
23. Galia, E., Nicolaides, E., Horter, D., Lobenberg, R., Reppas, C. and Dressman, J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and class II drugs. Pharm. Res., 15, 698 (1998)
24. Mainprize, T. and Grady, L.T. Standardization of an in vitro method of drug absorption. Pharm. Forum., 24 (2), 6015-6023 (1998).
25. Wojcik, R.C. Setting dissolution specifications. Dissol. Technol., 4 (3), 12-20 (1997).
26. Rudman, R. and Williams, R. Center for drug evaluation and research. Guidance for industry. Immediate release solid oral dosage forms. Scale-up and postapproval changes. Chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation, FDA. Rockville, MD (1995).
27. Moore, J.W. and Flanner, H.H. Mathematical comparison of dissolution profiles. Pharm. Technol., 20 (6) 64-74 (1996).